Rocket Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.69 Insider Own0.90% Shs Outstand64.51M Perf Week-3.81%
Market Cap529.31M Forward P/E- EPS next Y-1.93 Insider Trans-4.20% Shs Float59.67M Perf Month-35.85%
Income-171.90M PEG- EPS next Q-0.68 Inst Own98.60% Short Float12.67% Perf Quarter-52.08%
Sales- P/S- EPS this Y-6.00% Inst Trans1.32% Short Ratio14.47 Perf Half Y-73.97%
Book/sh6.47 P/B1.40 EPS next Y-11.40% ROA-34.00% Target Price57.89 Perf Year-77.78%
Cash/sh5.95 P/C1.53 EPS next 5Y10.80% ROE-37.20% 52W Range7.57 - 49.66 Perf YTD-58.36%
Dividend- P/FCF- EPS past 5Y-19.30% ROI- 52W High-81.23% Beta1.98
Dividend %- Quick Ratio15.70 Sales past 5Y- Gross Margin- 52W Low23.20% ATR1.02
Employees151 Current Ratio15.70 Sales Q/Q- Oper. Margin- RSI (14)38.31 Volatility15.12% 9.90%
OptionableYes Debt/Eq0.05 EPS Q/Q-2.10% Profit Margin- Rel Volume0.66 Prev Close9.09
ShortableYes LT Debt/Eq0.05 EarningsFeb 24 BMO Payout- Avg Volume522.57K Price9.32
Recom1.70 SMA20-13.24% SMA50-30.85% SMA200-59.73% Volume145,054 Change2.53%
Oct-20-21Resumed Cowen Outperform
Mar-02-21Initiated Stifel Buy $64
Feb-18-21Initiated Needham Buy $75
Dec-16-20Initiated UBS Buy $75
Dec-08-20Downgrade Oppenheimer Outperform → Perform
Jul-02-20Initiated JP Morgan Overweight
Jun-25-20Resumed BofA/Merrill Buy $34
Jun-01-20Resumed Oppenheimer Outperform
Nov-06-19Initiated Chardan Capital Markets Buy $30
Sep-26-19Initiated Piper Jaffray Overweight
Apr-23-19Initiated Robert W. Baird Outperform
Mar-15-19Initiated BofA/Merrill Buy $27
Feb-05-19Initiated Oppenheimer Outperform $39
Sep-13-18Initiated Ladenburg Thalmann Buy $30
Jul-10-18Initiated William Blair Outperform
May-16-22 06:00AM  
May-11-22 09:08AM  
May-05-22 04:01PM  
Apr-27-22 07:00AM  
Mar-29-22 07:00AM  
Mar-14-22 07:00AM  
Mar-08-22 07:00AM  
Feb-24-22 07:00AM  
Feb-10-22 07:00AM  
Feb-09-22 08:03PM  
Jan-11-22 07:00AM  
Jan-04-22 07:00AM  
Dec-22-21 09:41AM  
Dec-13-21 09:00AM  
Dec-08-21 07:00AM  
Dec-07-21 07:00AM  
Nov-22-21 07:00AM  
Nov-15-21 02:43PM  
Nov-11-21 07:00AM  
Nov-10-21 07:00AM  
Nov-09-21 10:45AM  
Nov-08-21 05:00AM  
Nov-04-21 09:00AM  
Nov-03-21 07:00AM  
Oct-29-21 11:47AM  
Oct-20-21 08:03AM  
Oct-19-21 06:00AM  
Oct-07-21 07:00AM  
Sep-30-21 07:00AM  
Sep-22-21 12:02PM  
Sep-20-21 11:50AM  
Sep-14-21 07:00AM  
Sep-10-21 07:00AM  
Sep-07-21 07:00AM  
Aug-30-21 07:00AM  
Aug-16-21 02:00PM  
Aug-09-21 04:01PM  
Aug-03-21 04:01PM  
Jul-19-21 12:08PM  
May-13-21 12:00PM  
May-11-21 12:28PM  
May-10-21 04:00PM  
Apr-27-21 04:30PM  
Apr-14-21 07:00AM  
Apr-12-21 04:50PM  
Mar-29-21 07:00AM  
Mar-22-21 07:00AM  
Mar-10-21 09:56AM  
Mar-09-21 07:00AM  
Feb-25-21 07:00AM  
Feb-18-21 10:02AM  
Jan-15-21 08:30PM  
Jan-11-21 07:00AM  
Jan-06-21 07:00AM  
Dec-18-20 12:10AM  
Dec-14-20 04:01PM  
Dec-10-20 10:52AM  
Dec-09-20 11:32PM  
Dec-08-20 04:00PM  
Dec-07-20 02:30PM  
Dec-06-20 10:00AM  
Dec-02-20 07:00AM  
Nov-24-20 07:00AM  
Nov-13-20 07:00AM  
Nov-04-20 10:37AM  
Oct-16-20 07:15AM  
Oct-13-20 12:04PM  
Oct-01-20 07:00AM  
Sep-24-20 07:00AM  
Sep-04-20 07:00AM  
Sep-02-20 07:00AM  
Aug-27-20 07:00AM  
Aug-26-20 07:00AM  
Aug-05-20 07:00AM  
Jul-13-20 07:00AM  
Jul-08-20 12:53PM  
Jun-29-20 07:00AM  
Jun-27-20 03:16PM  
Jun-08-20 07:00AM  
May-26-20 07:00AM  
May-12-20 07:00AM  
May-10-20 10:39PM  
May-06-20 07:00AM  
May-05-20 07:00AM  
Apr-22-20 07:00AM  
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwartz Jonathan DavidSee RemarksMar 30Sale16.4145,000738,652179,529Apr 01 04:51 PM
Shah GauravCEOFeb 07Buy17.3422,000381,513517,639Feb 08 04:43 PM
Makker GothamDirectorJun 17Sale47.1240018,8501,296,401Jun 21 04:52 PM
Makker GothamDirectorJun 16Sale46.8534,6851,624,8431,296,801Jun 21 04:52 PM